Triglyceride glucose-body mass index is effective in identifying nonalcoholic fatty liver disease in nonobese subjects.

Medicine (Baltimore)

Division of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Department of Health Examination Department of Endocrinology, Wuhan Iron and Steel Company (WISCO) General Hospital, Wuhan, Hubei Province, China.

Published: June 2017

AI Article Synopsis

  • Nonalcoholic fatty liver disease (NAFLD) is common in both obese and nonobese individuals, with a study showing a prevalence of 23.9% in nonobese Chinese adults.
  • The TyG-BMI index, which combines triglyceride and glucose levels with body mass index, is an effective marker for identifying NAFLD, showing a significant odds ratio of 3.4 for every standard deviation increase.
  • TyG-BMI outperformed its individual components in diagnosing NAFLD, proving to be a strong tool for recognizing nonobese individuals at risk for the disease.

Article Abstract

Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition that is highly correlated with obesity; however, it is not uncommon among nonobese individuals. Triglyceride (TG) and glucose index combined with body mass index (TyG-BMI) has been proposed as a favorable marker of insulin resistance. We sought to investigate the effectiveness of TyG-BMI in identifying NAFLD in nonobese subjects.We conducted a cross-sectional study in a nonobese (BMI <25.0 kg/m) Chinese population (N = 6809) of adults who underwent health examinations, including abdominal ultrasonography.The prevalence of ultrasonography-detected NAFLD was 23.9% in nonobese subjects. After adjusting for potential confounders, every 1-standard deviation increase in TyG-BMI had an odds ratio (OR) of 3.4 [95% confidence interval (95% CI), 3.0-3.9] for NAFLD. Compared with the lowest quartile of TyG-BMI, multivariable-adjusted ORs were 2.4 (1.6-3.6), 6.4 (4.2-9.7), and 15.3 (9.8-23.9) for those in the second, third, and fourth quartile, respectively. According to the receiver operating characteristic curve analysis, TyG-BMI was effective in diagnosing patients with NAFLD with an area under the curve of 0.835 (95% CI, 0.824-0.845). In comparison, TyG-BMI was superior to its components, including TyG, BMI, TG, and fasting plasma glucose, for identifying nonobese subjects at risk for NAFLD.In this study, the prevalence of NAFLD was over one-fifth in the nonobese population. TyG-BMI was an effective marker to detect NAFLD in nonobese subjects.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459725PMC
http://dx.doi.org/10.1097/MD.0000000000007041DOI Listing

Publication Analysis

Top Keywords

nonalcoholic fatty
8
fatty liver
8
liver disease
8
triglyceride glucose-body
4
glucose-body mass
4
mass effective
4
effective identifying
4
identifying nonalcoholic
4
nonobese
4
disease nonobese
4

Similar Publications

Alleviating batch effects in cell type deconvolution with SCCAF-D.

Nat Commun

December 2024

GMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macao Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Laboratory, Guangzhou Medical University, Guangzhou, China.

Cell type deconvolution methods can impute cell proportions from bulk transcriptomics data, revealing changes in disease progression or organ development. But benchmarking studies often use simulated bulk data from the same source as the reference, which limits its application scenarios. This study examines batch effects in deconvolution and introduces SCCAF-D, a computational workflow that ensures a Pearson Correlation Coefficient above 0.

View Article and Find Full Text PDF

Background: UpToDate, no drugs have been approved to treat nonalcoholic steatohepatitis, the advanced stage of the most prevalent liver disease, non-alcoholic fatty liver disease. The present study was conducted to explore the potential influences of L-carnitine on the pathomechanisms of hepatic injury that mediate progression to non-alcoholic steatohepatitis in dexamethasone-toxified rats.

Methods: Male Wistar rats were allocated as follows: dexamethasone group, rats received dexamethasone (8 mg/kg/day, intraperitoneally) for 6 days; DEXA-LCAR300, DEXA-LCAR500, and DEXA-MET groups, rats administered L-carnitine (300 or 500 mg/kg/day, IP) or metformin (500 mg/kg/day, orally) one week prior to dexamethasone injection (8 mg/kg/day, IP) and other six days alongside dexamethasone administration.

View Article and Find Full Text PDF

The Putative Antilipogenic Role of NRG4 and ERBB4: First Expression Study on Human Liver Samples.

Front Biosci (Landmark Ed)

December 2024

Center for Immunology and Cellular Biotechnology, Institute of Medicine and Life Sciences, Immanuel Kant Baltic Federal University, 236001 Kaliningrad, Russia.

Background: Epidermal growth factor receptor 4 (ERBB4) and neuregulin 4 (NRG4) have been shown to reduce steatosis and prevent the development of non-alcoholic steatohepatitis in mouse models, but little to nothing is known about their role in non-alcoholic fatty liver disease (NAFLD) in humans. This study is the first to investigate the expression of and mRNAs and their role in lipid metabolism in the livers of individuals with obesity, type 2 diabetes and biopsy-proven NAFLD.

Methods: Liver biospecimens were obtained intraoperatively from 80 individuals.

View Article and Find Full Text PDF

This study investigates the relationship between vitamin D levels and liver cirrhosis severity, a leading cause of global morbidity and mortality. Chronic liver diseases, stemming from conditions such as hepatitis, alcohol use, non-alcoholic fatty liver disease, autoimmune diseases, and cryptogenic disorders, disrupt vitamin D metabolism, as the liver converts dietary and skin-derived vitamin D into 25-hydroxyvitamin D (25[OH]D), the primary circulating form. The cross-sectional study conducted at the Department of General Medicine of BLDE (DU) Shri.

View Article and Find Full Text PDF

Resmetirom is a thyroid hormone receptor agonist that has been recently approved by the FDA for the management of metabolic dysfunction-associated steatohepatitis (MASH). MASH is a severe form of metabolic dysfunction-associated fatty liver disease (MASLD), which is marked by hepatic inflammation and potential progression to cirrhosis and liver cancer. This review analyzes and demonstrates the efficacy of resmetirom in reducing intra-hepatic lipids, improving liver histology, and improving metabolic parameters.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!